UnknownPhase 4

Naftopidil 75mg for Improving Clearance of Urinary Stones

South Korea130 participantsStarted 2014-02

Plain-language summary

The purpose of this study is to evaluate Efficacy and Safety of oral intake of Naftopidil 75mg once daily for the improving clearance of ureteral or renal stones.

Who can participate

Age range15 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Radio-opaque (identifiable in KUB) ureter or kidney calculi * size criteria is from 5mm to 15mm Exclusion Criteria: * Symptomatic acute urinary tract infection during the run-in period * severe hydronephrosis * 2 or more urinary stones * Radiolucent (non-visible in KUB) stone * recent intervention for the urinary stone within 6 month * Patients who have ureteral stent * over 2.0 mg/dl of serum creatinine level * severe hepatic dysfunction * orthostatic hypotension * current usage of alpha-adrenergic blocker or calcium channel blocker * Pregnant or nursing women * Age under 15 year * severe or uncontrolled medical conditions

What they're measuring

Difference of the treatment success rate in two weeks after ESWL between treatment group and placebo group

Timeframe: 2 weeks after ESWL

Trial details

NCT IDNCT02011737

SponsorSamsung Medical Center

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2015-02

Contact for this trial

Deok Hyun Han, MD

82-2-3410-6431 deokhyun.han@gmail.com

View on ClinicalTrials.gov More Kidney Calculi trials